4 Pharmaceutical Stocks to Buy Now

by Portfolio Grader | April 18, 2014 8:45 am

Four pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader[1] database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

This week, NuPathe Inc. (PATH[2]) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock[3].

This week, Watson Pharmaceuticals (WPI[4]) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock[5].

Mylan (MYL[6]) shows solid improvement this week. The company’s rating rises from a B to an A. Mylan is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock[7].

Impax Laboratories, Inc. (IPXL[8]) gets a higher grade this week, advancing from a C last week to a B. Impax Laboratories develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. For more information, get Portfolio Grader’s complete analysis of IPXL stock[9].

Louis Navellier’s proprietary Portfolio Grader[10] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[11].

Endnotes:

  1. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  2. PATH: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=PATH
  3. For more information, get Portfolio Grader’s complete analysis of PATH stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=PATH
  4. WPI: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=WPI
  5. For more information, get Portfolio Grader’s complete analysis of WPI stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=WPI
  6. MYL: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=MYL
  7. For more information, get Portfolio Grader’s complete analysis of MYL stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=MYL
  8. IPXL: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=IPXL
  9. For more information, get Portfolio Grader’s complete analysis of IPXL stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=IPXL
  10. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  11. here: https://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: https://investorplace.com/2014/04/4-pharmaceutical-stocks-to-buy-now-path-wpi-myl-8/